Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Reckitt ( (GB:RKT) ) just unveiled an update.
Reckitt Benckiser Group plc has announced that non-executive director Harry Kirsch has joined the board of Swiss-listed dermatology company Galderma as a director, effective 22 April 2026. The cross-board appointment signals an additional external governance commitment for Kirsch, potentially broadening his industry insights and network as he continues to serve on Reckitt’s board, though the company has not indicated any direct change to its own operations or strategy.
The most recent analyst rating on (GB:RKT) stock is a Buy with a £62.00 price target. To see the full list of analyst forecasts on Reckitt stock, see the GB:RKT Stock Forecast page.
Spark’s Take on RKT Stock
According to Spark, TipRanks’ AI Analyst, RKT is a Neutral.
The score is driven primarily by improved financial performance (notably profitability and lower leverage) and supportive valuation (moderate P/E and solid yield). These are tempered by weak technicals (below key moving averages with negative momentum) and earnings-call-flagged near-term pressures on cash flow, leverage, and 2026 margin/EPS visibility.
To see Spark’s full report on RKT stock, click here.
More about Reckitt
Reckitt Benckiser Group plc is a global consumer goods company focused on health, hygiene and home care products. Its portfolio includes well-known brands such as Dettol, Durex, Finish, Gaviscon, Harpic, Lysol, Mucinex, Nurofen, Strepsils, Vanish and Veet, with a strategic emphasis on science-backed solutions that promote cleaner, healthier living.
Average Trading Volume: 2,197,415
Technical Sentiment Signal: Sell
Current Market Cap: £31.57B
For a thorough assessment of RKT stock, go to TipRanks’ Stock Analysis page.